A 14‐Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma

Sykes, Erin; McDonald, Cassandra E.; Ghazanfar, Shila; Mactier, Swetlana; Thompson, John F.; Scolyer, Richard A.; Yang, Yee Hwa; Mann, Graham J.; Christopherson, Richard I.

doi:10.1002/prca.201700094

Cited by 1 publication

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is increasingly recognized that comprehensive molecular profiling can increase survival among cancer patients through the detection of actionable biomarkers and the expansion of treatment options [11,12]. In the context of metastatic melanoma, characterization of protein, mRNA, and gene expression can inform on disease prognosis and response to targeted therapy against cancer-driving mutations [15][16][17]. Common mutations found in melanoma include the BRAF, NRAS, and TERT genes and have all been linked to worse prognosis [18][19][20].…”

Section: Discussionmentioning

confidence: 99%

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report

Dawood,

Ali

2023

Case Rep Oncol

View full text Add to dashboard Cite

Introduction: The burden of melanoma is increasing globally. Despite the use of immunotherapy and targeted therapy, the prognosis of metastatic melanoma remains relatively poor. The integration of comprehensive molecular profiling can lead to the detection of actionable biomarkers and the expansion of treatment options, thereby prolonging cancer patient survival. Case Presentation: We herein present the case of a female 54-year-old patient diagnosed with melanoma of the right knee, for which she underwent surgery. Patient showed progression of disease after 10 cycles of adjuvant nivolumab. Ipilimumab (1 mg/kg every 3 weeks) was added to the treatment regimen but no clinical improvement was observed. Molecular profiling was conducted based on patient tissue, and an ANXA2-NTRK3 fusion was detected in the tumor. This specific fusion has not been previously reported; however, it is in-frame and similar to other known oncogenic NTRK fusions. At the time of entrectinib initiation, the patient had clear disease progression on the right leg on standard of care immunotherapy. She was commenced on entrectinib 200 mg once daily for 2 weeks. Dose escalation was attempted, and treatment intensity was managed based on drug tolerability. Good treatment response was observed on laboratory and radiologic parameters. As of September 2023, i.e., 2.5 years after treatment initiation, patient disease continues to be controlled with entrectinib. Conclusion: Profiling of advanced tumors is important to determine the presence of agnostic markers that can be targeted and ultimately improve the prognostic outcome of patients after the failure of standard of care.

show abstract

Section: Discussionmentioning

confidence: 99%

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report

Dawood,

Ali

2023

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

A 14‐Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma

Abstract: The ten differential proteins identified by SRM have biological significance in cancer progression. The final signature of 14 proteins identified by SRM could be used to identify AJCC stage III melanoma patients likely to have poor outcomes who may benefit from adjuvant systemic therapy.

Cited by 1 publication

References 81 publications

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report

Contact Info

Product

Resources

About